スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

acino pharma ag - levetiracetamum - compresse rivestite con film - levetiracetamum 500 mg, arom.: vanillinum, colore.: e 104, conserv.: e 200, excipiens pro compresso haze. - antiepileptikum - synthetika

スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

acino pharma ag - levetiracetamum - compresse rivestite con film - levetiracetamum 1000 mg, excipiens pro compresso haze. - antiepileptikum - synthetika

スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

orpha swiss gmbh - loxapinum - einzeldosiertes polvere per inalazione - loxapinum 9.1 mg polvere per dosi. - antipsicotico - synthetika

欧州連合 - イタリア語 - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - avatrombopag maleate - trombocitopenia - antiemorragici - doptelet è indicato per il trattamento della trombocitopenia grave, in pazienti adulti con malattia cronica di fegato che sono in programma di sottoporsi a una procedura invasiva. doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (itp) in adult patients who are refractory to other treatments (e. corticosteroidi, immunoglobuline).

欧州連合 - イタリア語 - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - emapalumab - immune system diseases - gamifant is indicated for the treatment of paediatric patients aged under 18 years with primary haemophagocytic lymphohistiocytosis (hlh).

欧州連合 - イタリア語 - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - pegcetacoplan - emoglobinuria, parossistica - immunosoppressori - aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh) who are anaemic after treatment with a c5 inhibitor for at least 3 months.

スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

orpha swiss gmbh - landiololum - polvere per soluzione per infusione - landiololi hydrochloridum 300 mg corresp. landiololum 280 mg, mannitolum, natrii hydroxidum corresp. natrium max. 4.6 mg, pro vitro. - hoch selektiver beta-1-adrenorezeptor-antagonist - synthetika

欧州連合 - イタリア語 - EMA (European Medicines Agency)

aop orphan pharmaceuticals gmbh - sugammadex sodium - blocco neuromuscolare - tutti gli altri prodotti terapeutici - inversione del blocco neuromuscolare indotto da rocuronio o vecuronio. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.